Replies to post #107606 on Biotech Values

[DewDiligence]

…and then Spek said SNY would be ready [with an AG] when the right scenario occurs…

Spek immediately followed that up by saying that the proper time had not come.

I agree that he was probably referring to an additional generic entering the market.

This is definitely what Spek was referring to.

As long as m-enox maintains a 40-60% market share range there is no logic in introducing an AG.

Correct.